作者: Xin Liu , Xiu-Jie Wang
DOI: 10.1101/2020.01.29.924100
关键词: Virology 、 Ritonavir 、 M-protease 、 Binding pocket 、 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 、 Mutation 、 Lopinavir 、 Coronavirus 、 Medicine
摘要: Abstract Starting from December 2019, a novel coronavirus, named 2019-nCoV, was found to cause Severe Acute Respiratory (SARI) symptoms and rapid pandemic in China. With the hope identify candidate drugs for we adopted computational approach screen available commercial medicines which may function as inhibitors Mpro of 2019-nCoV. Up 10 that form hydrogen bounds key residues within binding pocket 2019-nCoV were identified, have higher mutation tolerance than lopinavir/ritonavir also other coronaviruses with similar sites structures.